1. Home
  2. MBOT vs IMUX Comparison

MBOT vs IMUX Comparison

Compare MBOT & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Microbot Medical Inc.

MBOT

Microbot Medical Inc.

HOLD

Current Price

$1.73

Market Cap

166.6M

Sector

Health Care

ML Signal

HOLD

Logo Immunic Inc.

IMUX

Immunic Inc.

HOLD

Current Price

$14.18

Market Cap

152.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MBOT
IMUX
Founded
2010
2016
Country
United States
United States
Employees
N/A
66
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
166.6M
152.6M
IPO Year
2000
2013

Fundamental Metrics

Financial Performance
Metric
MBOT
IMUX
Price
$1.73
$14.18
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
6
Target Price
$7.50
$36.00
AVG Volume (30 Days)
1.6M
253.5K
Earning Date
05-15-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
60.27
38.00
EPS
N/A
N/A
Revenue
$116,887.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$119.77
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.60
$0.51
52 Week High
$4.62
$14.69

Technical Indicators

Market Signals
Indicator
MBOT
IMUX
Relative Strength Index (RSI) 33.23 80.68
Support Level $1.65 $0.74
Resistance Level $2.23 N/A
Average True Range (ATR) 0.12 1.16
MACD -0.02 -0.15
Stochastic Oscillator 11.85 84.87

Price Performance

Historical Comparison
MBOT
IMUX

About MBOT Microbot Medical Inc.

Microbot Medical Inc is a medical device company specializing in the research, design, and development of next-generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. Using its LIBERTY technological platform, the company has developed the LIBERTY Endovascular Robotic Surgical System, a fully disposable robot for various endovascular interventional procedures. The company has a single operating and reportable segment, which is the development of robotic devices for endoluminal surgery.

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.

Share on Social Networks: